DD-234 (Methylscopolammonium methylsulfate), a new synthetic antispasmodic agent was evaluated of its clinical efficacy. It proved to be a fast-acting antispasmodic to reduce the secretion of human gastric juice and acid enhanced by stimulation with Histalog, and to exhibit its efficacy upon the colonic electro-myogram as well as intracolonic pressure curve by reducing the electric and motor activities of the intestinal tract. Evaluation of efficacy of DD-234 orally administered to patients with abdominal pain was made on double blind test basis, wherein a trend was observed that this drug mainly acts effectively upon abdominal pain derived from peptic ulcer, chronic gastritis and other gastrointestinal diseases and that its two times higher dose than ordinary use reduces the frequency of serious diarrhea.
Judging from the above observatioas, DD-234 may be evaluated to be useful for clinical use as a new antispasmodic.
